Controversies in BMT for Lymphoma
Controversies in BMT for Lymphoma
复制标题
DOI：
10.1016/j.bbmt.2012.10.024
复制
发表时间：
2013-01-01
影响因子：
4.3
通讯作者：
Shea, Thomas C.
中科院分区：
文献类型：
--
作者：
Gascoyne, Randy D.;Moskowitz, Craig;Shea, Thomas C.
以下教育补充“弥漫性大B细胞淋巴瘤的争议”地址三个主要领域。第一部分，“生物学弥漫性大B细胞淋巴瘤，”集中在最近的进展，了解这种疾病的发病机制和生物学与聚光灯上的新分类方法，应导致改善理解和治疗这种疾病。第二部分，“复发性和原发性难治性弥漫性大B细胞淋巴瘤的挽救治疗现状”，讨论了最近的试验，这些试验为接受自体造血干细胞移植（HSCT）的患者在使用含利妥昔单抗的诱导方案进行初始治疗失败后的结局提供了新的基准。本节回顾了一些新的预后数据，这些数据将有助于将患者分类为自体HSCT后预后良好或不良的患者，以及如何需要新的挽救方案来改善这些结果。第三部分，“造血干细胞移植预处理方案和弥漫性大B细胞淋巴瘤的移植后维持治疗”，评估了各种新型和传统预处理方案的结果，包括使用放射免疫治疗和异基因造血干细胞移植治疗预后不良的患者。本节还描述了新药物作为自体HSCT后维持治疗的潜在用途。
The following educational supplement on “Controversies in Diffuse Large B Cell Lymphoma” addresses three primary areas. The first section,“Biology of Diffuse Large B Cell Lymphomas,” focuses on recent advances in understanding the pathogenesis and biology of this disorder with a spotlight on new classification methods that should lead to improved understanding and treatment of this disease. The second section,“State of Salvage Therapy for Relapsed and Primary Refractory Diffuse Large B Cell Lymphoma,” addresses recent trials that have provided a new benchmark for outcomes of patients undergoing autologous hematopoietic stem cell transplantation (HSCT) after failing initial therapy with rituximab-containing induction regimens. This section reviews some of the new prognostic data that will help categorize patients into those with a good or poor prognosis after autologous HSCT and how novel salvage regimens are needed to improve these results. The third section,“Hematopoietic Stem Cell Transplantation Conditioning Regimens and Post-Transplant Maintenance Therapy for Diffuse Large B-Cell Lymphoma,” assesses outcomes achieved with a variety of novel and conventional conditioning regimens, including the use of radioimmunotherapy and allogeneic HSCT for poor-prognosis patients. This section also describes potential uses for new agents as maintenance therapy after autologous HSCT.